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Patients with treatment refractory Crohn’s disease (CD) suffer debilitating symptoms, 
poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic 
intestine may mandate creation of a stoma and is often declined by patients. Such 
patients continue to be exposed to medical therapy that is ineffective, often expensive 
and still associated with a burden of adverse effects. Over the last two decades, autolo-
gous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising 
treatment option for patients with severe autoimmune diseases (ADs). Mechanistic stud-
ies have provided proof of concept that auto-HSCT can restore immunological tolerance 
in chronic autoimmunity via the eradication of pathological immune responses and a 
profound reconfiguration of the immune system. Herein, we review current experience 
of auto-HSCT for the treatment of CD as well as approaches that have been used to 
monitor immune reconstitution following auto-HSCT in patients with ADs, including CD. 
We also detail immune reconstitution studies that have been integrated into the random-
ized controlled Autologous Stem cell Transplantation In refractory CD—Low Intensity 
Therapy Evaluation trial, which is designed to test the hypothesis that auto-HSCT using 
reduced intensity mobilization and conditioning regimens will be a safe and effective 
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iNTRODUCTiON
etiology, epidemiology, and Management 
of Crohn’s Disease (CD)
The intestinal inflammation associated with CD is caused by 
mucosal immune system reactivity to luminal antigen in geneti-
cally susceptible individuals. Active intestinal inflammation is 
associated with dysbiosis of the fecal and mucosal microbiota 
and increased intestinal permeability with alterations in innate 
lymphoid cell (ILC) populations. Defects in the innate immune 
pathway in CD are implicated by pathogenic mutations in the 
nucleotide-binding oligomerization domain 2 (NOD2) and 
autophagy-related protein 16-1 (ATG16L1) genes which suggest 
impairment of bacterial sensing and clearance. CD is associated 
with increased IL-12/IL-23 release from antigen-presenting cells 
and an imbalance in the differentiation of Th1/Th17 effector and 
regulatory lymphocytes (1, 2).
The incidence of CD is increasing in young adults who live 
with their disease for six decades (3). In addition, there has been a 
significant increase in CD incidence in newly industrialized coun-
tries of Africa, Asia, and South America (4). The prevalence of CD 
in the UK stands at approximately 145/100,000 (5) with 9.5 new 
cases per 100,000 annually (6). The highest prevalence in North 
America is reported in Canada at 319/100,000 (4). Traditional 
medical management focuses on controlling intestinal inflam-
mation using conventional or biological therapy. Although many 
patients respond to first line biologic therapy, a recent prospective 
UK registry of 1,500 patients with CD commencing their first 
anti-TNF therapy reports primary non-response in between 16.9 
and 23.7% of patients (7) and a secondary loss of response in a 
further 29% of patients over 2 years (7).
Recent single and multicenter cohort studies have reported 
a significant burden of adverse events with anti-TNF therapies 
including an increased risk of lymphoma independent of the 
use of concomitant thiopurine therapy (8, 9). The anti-integrin 
vedolizumab and the IL-12/23 antibody ustekinumab are both 
licensed as second-line biologic therapy for refractory CD. 
However, both therapies are less effective at inducing and main-
taining remission in patients that have been exposed to anti-TNF 
therapy previously (10). Although novel biological therapies are 
in clinical development none have reported short- or long-term 
remission rates in more than 50% patients. Furthermore, biologic 
therapies currently constitute the largest proportion of the total 
treatment costs of patients with CD (11).
Patients refractory to medical therapy and those who develop 
stricturing or penetrating complications of disease progression 
require surgical resection of the affected intestine (12). However, 
disease recurrence after surgery is common and many patients 
face repeated or extensive surgeries that may require a stoma or 
result in short bowel syndrome and a requirement for parenteral 
nutrition support. Although the introduction of biologic therapies 
has been associated with a reduction in the rates of surgery over 
the recent decade, there has been no reduction in the requirement 
for repeat surgery (13). Patients with active disease refractory to 
currently licensed therapies in whom surgery is inappropriate or 
declined face ineffective biologic therapy and frequent courses of 
corticosteroids which are associated with a significant burden of 
treatment-related morbidity and mortality and high health-care 
resource utilization (11). There is a clear unmet need for an effec-
tive long-term therapy for this cohort of patients.
Clinical Studies investigating Auto-HSCT 
for CD
Over the last two decades, autologous hematopoietic stem cell 
transplantation (auto-HSCT) has been identified as a promising 
therapeutic option for patients with severe autoimmune diseases 
(ADs). Mechanistic studies suggest that restoration of immu-
nological tolerance in chronic autoimmunity occurs after auto-
HSCT via eradication of immune memory and reconfiguration of 
the immune system. Although case reports suggested exceptional 
benefit for patients with refractory CD after auto-HSCT (14, 15), 
concerns about safety and a lack of understanding as to whether 
benefit relates to the chemotherapeutic agents administered 
during mobilization/pre-transplant conditioning regimen or the 
transplant itself, led to the Autologous Stem cell Transplantation 
International Crohn’s disease (ASTIC) randomized controlled 
trial (NCT00297193) (16, 17). This was conducted at 11 accred-
ited centers in 6 European countries (16, 17).
Autologous Stem cell Transplantation International Crohn’s 
disease compared cyclophosphamide mobilization alone to 
mobilization, high-dose chemotherapy, and auto-HSCT in 
patients with refractory CD (16, 17). Eligible patients under-
went peripheral blood stem cell mobilization with high-dose 
cyclophosphamide (4 g/m2) and granulocyte colony-stimulating 
factor (G-CSF), after which they were randomized to immediate 
auto-HSCT or conventional care for 1 year (16, 17).
The primary endpoint for the trial was defined as clinical dis-
ease remission (CDAI < 150) for 3 months, with no medication for 
CD and no evidence of active disease on imaging and endoscopy 
at 1 year. Few patients randomized to immediate HSCT or who 
underwent mobilization and were then randomized to conven-
tional care achieved the ambitious primary endpoint at 1  year. 
means of inducing sustained control in refractory CD compared to standard of care. 
Immunological profiling will generate insight into the pathogenesis of the disease, resto-
ration of responsiveness to anti-TNF therapy in patients with recurrence of endoscopic 
disease and immunological events that precede the onset of disease in patients that 
relapse after auto-HSCT.
Keywords: autologous stem cell transplantation, Crohn’s disease, hematopoietic stem cell transplantation, 
immune reconstitution, inflammatory bowel diseases, T cell receptor repertoire
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However, ASTIC did demonstrate benefits of auto-HSCT over con-
ventional care in more traditional endpoints for therapeutic trials 
in this area (18), such as steroid-free clinical remission (CR) and 
mucosal healing (16). In addition, after the primary endpoint had 
been assessed, patients who had undergone mobilization and then 
been randomized to conventional care were offered auto-HSCT 
and then followed for a further year with identical assessments 
as in the randomized trial. Subsequent analysis of the 38 patients 
who underwent auto-HSCT in the ASTIC program and had data 
at baseline and 1 year reported a significant reduction in clinical 
and endoscopic disease activity at 1 year, with 19 out of 38 (50%) 
patients showing regression of all endoscopic ulceration (17). 
There were also significant improvements in quality of life between 
baseline and 1  year after auto-HSCT (17, 19, 20). Importantly, 
disease recurrence after HSCT responded to the introduction 
of anti-TNF therapies (15, 17). The doses of cyclophosphamide 
used in both groups resulted in significant numbers of adverse 
events and one death (17, 21, 22). Subsequent expert review has 
suggested that the high dose cyclophosphamide regimen used at 
both mobilization and conditioning was a factor for many of the 
adverse events (17, 21, 22). This view is supported by the outcome 
of an uncontrolled series of 14 patients with refractory Crohn’s 
disease (CD) who underwent auto-HSCT using a lower dose of 
cyclophosphamide during mobilization (2 g/ m2) and condition-
ing (50 mg/kg for 4 days). The median duration of anemia and 
neutropenia was shorter after both mobilization and conditioning 
than that seen in previous reports using higher cyclophosphamide 
dosing, and few episodes of febrile neutropenia were reported. 
The lower intensity regimen still resulted in marked reduction in 
clinical disease activity with 13 patients achieving disease remis-
sion (CDAI < 150) at 30 days (20).
In addition, favorable long-term outcome after auto-HSCT 
in a single-center cohort of 29 patients with CD (some of 
whom participated in the ASTIC trial) has been described (23). 
This includes 5-year follow-up data with scheduled clinical, 
endoscopic and radiological assessment. Drug-free clinical and 
endoscopic remission (CDAI < 150, SES-CD < 7) was seen in 
61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 
15% at 5 years. However, 80% of those patients who experienced a 
relapse responded to the re-introduction of anti-TNF therapy. Six 
out of the 29 underwent surgery after auto-HSCT, and 1 patient 
died of CMV infection.
Current Data on HSCT for CD From the 
eBMT Autoimmune Disease working  
Party (ADwP) Registry
The long-term outcomes for all adult patients undergoing auto-
HSCT for CD in Europe between 1997 and 2015 (outside the 
ASTIC study) have been evaluated using the EBMT registry. 
Clinical data were obtained for 82 patients from 19 centers in 7 
countries, with clinical response being categorized as remission 
(no abdominal pain and normal stool frequency), significant 
improvement (improved pain and frequency), no change, or 
worsening of symptoms.
Median follow-up was 41 months (range 6–174). At 100 days 
post-HSCT, 64% of patients were in CR and a further 28% had 
experienced significant improvement. At 1 year after transplanta-
tion, data from 75 patients indicated that 43% were in CR, 20% 
improved, 17% unchanged and 20% worsened. 37% patients 
required surgery after auto-HSCT, and 73% re-started medical 
therapy. Of those requiring further treatment, 57% responded to 
therapies to which they had previously been refractory. Treatment-
free survival, defined as survival without major surgery or medi-
cal therapy, was 27 and 22% at 3 and 5 years respectively.
In addition, the EBMT ADWP has produced a historical 
summary of the AD section of the registry, which has charac-
terized outcomes following auto-HSCT in various indications. 
Compared with MS, relapse is more common in CD, which may 
reflect fundamental differences in disease processes (24).
As of November 2017, there have been a total of 166 transplant 
registrations for auto-HSCT of CD within the EBMT registry, 
with the majority 91.5% being in adults over 18 and 24% being 
treated as part of the ASTIC trial. Patients are predominantly 
being treated in Spain, UK, Italy, Belgium, The Netherlands, and 
France (Figure 1) (source, EBMT Office, Paris).
Taken together, current experience indicates that auto-HSCT 
can induce clinical and endoscopic remission, but does not result 
in sustained treatment-free disease remission in most patients. 
However, many patients become responsive to treatments to 
which they were previously refractory. Biomarkers that predict 
which patients will respond to anti-TNF therapy after auto-HSCT 
have not been identified and should be a focus of future trials in 
this area. In addition, auto-HSCT regimens including high dose 
cyclophosphamide are associated with significant adverse events, 
which may be avoided with lower intensity regiments. Hence 
further randomized controlled trials that assess the benefit of 
lower intensity regimens are warranted.
iMMUNe ReCONSTiTUTiON FOLLOwiNG 
AUTO-HSCT FOR CD
Specific studies of immune reconstitution in CD patients after 
auto-HSCT are limited to a few observations (25, 26). Therefore, 
this review focuses on the general literature relating to immune 
reconstitution in ADs and highlights how it might be best inves-
tigated in patients with CD to identify mechanisms of action of 
auto-HSCT and gain insights into the pathogenesis of CD.
Rationale and Mechanistic Studies of 
Auto-HSCT for ADs
The original goal of auto-HSCT in ADs was to eradicate existing 
autoreactive immunological memory and regenerate a naïve, self-
tolerant immune system (27, 28). Auto-HSCT has been shown to 
profoundly impact the immune system, as indicated by the regen-
eration of naïve B cells (29, 30), thymic reactivation (29, 31–33), 
the emergence of a polyclonal T cell receptor (TCR) repertoire 
(29, 31, 33), and restoration of Foxp3+ regulatory T (Treg) (34, 
35) and B regulatory cell levels (36). In addition, disease associ-
ated restriction of the peripheral blood Treg TCR repertoire is 
completely reversed by auto-HSCT, both in terms of number and 
uniqueness of Treg cell TCR sequences (37). Functional assays 
investigating the fate of autoreactive T cells post-transplantation 
FiGURe 1 | Registrations per year for the treatment of Crohn’s disease using autologous hematopoietic stem cell transplantation (auto-HSCT) within the EBMT 
registry 1994–2017 (note data for 2017 up to November 2017)—numbers treated on the Autologous Stem cell Transplantation International Crohn’s disease (ASTIC) 
trial are indicated in blue. Patients have been predominantly treated in Spain, UK, Italy, Belgium, The Netherlands, and France in reducing order (source EBMT 
Office, Paris).
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are limited due to restricted access to such cell clones in human 
disease compared to animal models. Nevertheless, in vitro stimu-
lation assays in SLE have been able to demonstrate that T  cell 
responses to antinuclear antigens were abolished, whereas virus-
specific T cells were readily detectable in the first months after 
HSCT (29). Likewise, stimulation assays with myelin oligoden-
drocyte glycoprotein peptides in auto-HSCT-treated MS patients 
revealed reduced interleukin-17 responses and enhanced trans-
forming growth factor-β1 production compared to natalizumab- 
treated patients, suggesting removal of autoreactive T cell clones 
as well as enhanced suppressive responses after HSCT (38). 
Collectively, these observations suggest that auto-HSCT has 
indeed the potential to restore self-tolerance by “resetting” the 
chronic autoreactive immune system into a naïve state.
Compared with MS and rheumatological diseases, there are 
relatively little data specifically relating to immune reconstitution 
following auto-HSCT in CD. The following sections will discuss 
how components of aberrant immunity may be investigated 
further in CD.
impact of Auto-HSCT for CD on the innate 
immune System
The intestinal innate immune system not only protects against 
invading pathogens, it also regulates the interactions between 
the commensal intestinal microbiota and the host at multiple 
levels, many of which are altered in CD. A small study investi-
gating the effect of auto-HSCT on the innate immune system in 
seven patients with moderate to severe CD has reported elevated 
numbers of peripheral blood TLR-4 expressing monocytes that 
also express TNF-alpha and IFN-gamma at baseline compared 
to healthy controls, which were normalized after transplantation 
(25). The impact of auto-HSCT on other intestinal innate immune 
populations has not been assessed. Studies on ILCs would be of 
particular relevance given their role in orchestrating immune 
defense and regulation at mucosal surfaces and their role in CD 
pathogenesis.
impact of Auto-HSCT for CD on the 
Adaptive immune System
The increased responses of CD4+ Th17/Th1  cells toward 
bacterial-derived proteins that have been described in patients 
with CD suggest a potential mechanism for sustaining persistent 
disease (39). Elimination of such cells in vivo by immunoablative 
chemotherapy is presumed to ameliorate intestinal inflammation. 
Conversely, recurrence of regulatory Foxp3+ Treg cells could 
restore self-regulation. The first investigation of the impact of 
auto-HSCT on peripheral blood lymphocytes in patients with CD 
demonstrated restoration of dysregulated T effector cell responses 
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with a normalization in the number of IFN-gamma-secreting 
CD4+ T cells together with a significant increase in Foxp3+ Treg 
cells (25). Interestingly, early restoration of circulating Treg 
numbers was predictive for treatment response at 3  months 
post-transplantation.
impact of Auto-HSCT for CD on TCR 
Repertoire Profile
The extensive immune renewal that follows auto-HSCT is associ-
ated with a vast diversification of the TCR repertoire. For example, 
in MS, CD4+ T cell dominant TCR clones that were present in 
peripheral blood before treatment were undetectable after 
immune reconstitution, with patients predominantly developing 
a new repertoire. More importantly, the T  cell repertoire early 
during the reconstitution process were less diverse in patients 
who failed to respond to treatment (40). However, these data were 
exclusively obtained from peripheral blood and not from the site 
of inflammation. By contrast, next-generation sequencing (NGS) 
of the TCRβ locus in ileal and colonic biopsies collected at baseline 
(pre-mobilization) and after auto-HSCT (6 months and/or 1 year 
after transplantation) has been used to correlate TCR diversity 
with clinical and endoscopic outcome in 16 patients with CD (26). 
Quantifying repertoire similarities of T cell clones at different time 
points were quantified by the Morisita–Horn index (M–H; range 
0–1) revealed monoclonal expansions in the mucosal T cell com-
partment at baseline prior to HSCT. The TCR repertoire was more 
polyclonal than expected (500 to 20,000 unique TCR sequences, 
clonality index 0.1 to 0.3), with no shared public TCR sequences 
being apparent in the mucosa of different patients. The clonality of 
the TCR in the mucosa was significantly increased after HSCT and 
the T cell repertoire appears reset, as the similarity index between 
baseline and after the procedure was low (26).
impact of G-CSF on immune 
Reconstitution Post Auto-HSCT in CD
Granulocyte colony-stimulating factor is given both to mobilize 
hematopoietic stem cells and to accelerate neutrophil recovery 
post auto-HSCT. However, it can profoundly affect innate and 
adaptive immunity by inducing the differentiation of type 1 Treg 
cells and tolerogenic dendritic cells (DCs) (41). Clinical benefit 
from G-CSF was reported in five patients with severe endoscopic 
postoperative recurrence of CD who received 300 µg of recom-
binant human G-CSF three times per week for 12 consecutive 
weeks (42). Administration of G-CSF was safe and associated 
with significant increases in neutrophil counts, and levels of IL-1 
receptor antagonist and soluble TNF receptor p55 and p75.
A clinical trial in nine patients with CD at the USA National 
Institutes of Health confirmed the potential benefit of subcutane-
ous G-CSF given over a 4-week period (43). In this study, changes 
in immune cell phenotypes, including myeloid and plasmacytoid 
DCs, as well as cytokine production were measured in the periph-
eral blood and colonic mucosal tissues. Patients who responded 
to G-CSF or achieved CR had significantly more IL-10-producing 
CD4+ memory T cells in the periphery, as well as a greatly enhanced 
CD123+ plasmacytoid DC infiltration of the lamina propria. 
Interestingly, IFN-γ production was higher in non-responders 
to G-CSF compared with responders. Although a randomized 
controlled placebo trial has not yet been performed, these studies 
suggest that G-CSF per se might offer some therapeutic benefit 
for patients with CD. Whether stem cell mobilization with G-CSF 
affects the functional orientation of immune cell populations in 
patients with CD and whether G-CSF-mobilized immune cell 
subsets, such as Treg cells and/or plasmacytoid DCs, favor the 
re-establishment of immune tolerance after auto-HSCT remains 
to be evaluated.
Does Auto-HSCT induce a Reset or 
Temporary Downregulation of immunity  
in CD?
It is essential to determine whether there is a real “reset” of auto-
immunity following auto-HSCT for CD, as has been observed for 
multiple sclerosis and systemic lupus erythematosus and which 
forms the basis for treatment-free remissions, or simply a tempo-
rary downregulation of innate and acquired immune responses. 
The relapse rate in CD after auto-HSCT is considerably higher 
compared to other ADs, which could be related to an insufficient 
eradication of the autoreactive immunologic memory by the 
conditioning regimens applied and/or a more prominent genetic 
contribution that favors disease recurrence. The latter fact is 
supported by epidemiologic studies demonstrating concordance 
rates among monozygotic twins of up to 50% (44). Alternatively, 
failure of achieving durable treatment-free remissions in CD 
post-transplantation could indicate that aberrant adaptive auto-
immune responses and formation of a pathogenic immunologic 
memory are not the driving force in disease pathogenesis, as 
confirmed for other systemic ADs. In fact, perturbations in the 
innate immune pathway resulting in compromised mucosal bar-
rier functions may have a stronger implication in driving chronic 
autoimmune responses in CD, which may not be corrected by 
“resetting” the immune system with auto-HSCT. Data supporting 
these considerations are not available yet, as studies investigat-
ing the influence of intestinal epithelial barrier changes on the 
dysfunction of mucosal innate and acquired immune responses 
after auto-HSCT in patients with CD are lacking.
Future Directions for immune Monitoring 
After Auto-HSCT in CD
Guidelines and expert recommendations to develop and imple-
ment systematic approaches to monitor immune responses in 
patients with cancer have been recently published (45). Likewise, 
the EBMT Autoimmune Diseases and Immunobiology Working 
Parties have initiated a joint process to develop and implement 
guidelines for “good laboratory practice” to provide practical 
recommendations for biobanking and immune monitoring 
in patients with ADs undergoing HSCT (46). The analysis of 
biological specimens at the cellular, DNA, transcriptional, epige-
netic, posttranscriptional, and protein levels, including peripheral 
blood and tissues, yields a massive amount of data, which need to 
be processed with novel bioinformatics methods.
For the analysis of TCR repertoire, several different approaches 
and methods exist. The approach to be used is dependent on the 
experimental questions being asked and methodological bias can 
make it difficult to compare results across different studies. The 
latest advances, available tools, the choice of starting material, and 
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the method for preparing samples have been reviewed in detail 
elsewhere (47). Most of the approaches involve the analysis of sam-
ples at the molecular level, commonly using deep and NGS (47).
Comprehensive protocols relating to multi-parameter flow 
cytometric analysis have been published previously (48, 49). In 
the future, such conventional flow cytometry may be combined 
with methods providing higher resolution, such as cytometry 
by time of flight mass spectrometry, as has already been used by 
Karnell and colleagues to investigate the kinetics of immune cell 
subset reconstitution in the periphery after HSCT and the impact 
of HSCT on the phenotype of circulating T cells in patients with 
MS (50). In addition, cytometric profiling may be complemented 
by an innovative flow cytometry approach which combines three 
monoclonal antibodies with two fluorophores to quantitate the 
TCR Vβ repertoire of human T lymphocytes (IOTest® Beta Mark 
TCR V-beta Repertoire Kit, Beckman Coulter).
Analysis of T Cell Reconstitution Based  
on T Cell Receptor excision DNA Circles 
(TReCs)
T  cell reconstitution after successful HSCT can occur via a 
thymic-independent pathway, which involves the expansion 
of graft-derived mature donor T cells, or a thymic-dependent 
pathway, the consequence of which is a regeneration of T cells 
with a more diverse TCR repertoire from graft-derived precur-
sor cells (51). As thymic function is required for the de novo 
generation of T cells after transplantation, the potential func-
tion of T lymphopoiesis after auto-HSCT can be determined by 
quantifying TRECs (52). Signal joint TCR excision DNA circles 
(sjTRECs) result from the rearrangement of the TCR gene and 
the excision of circular DNA fragments from genomic DNA 
during thymocyte development. Measuring thymic function by 
quantifying sjTRECs in peripheral blood avoids disadvantages 
that are associated with the use of T cell surface molecules, such 
as CD45RA, as markers for recent thymic emigrants (RTEs). 
sjTRECs reflect developmental proximity to the thymus and the 
analysis of total sjTRECs levels and TCR beta variable region 
(TRBV) subfamily sjTRECs frequencies during immune recon-
stitution after HSCT is useful for more precisely determining 
thymic output function and T  cell immune reconstitution 
(53). Although such analyses have not yet been undertaken 
in the context of CD, the increased precision of this approach 
has the potential to provide a more robust insight into the 
relationship(s) between immune status, disease status, and 
therapeutic resistance after auto-HSCT.
FiGURe 2 | Proposed approach to immune monitoring in the Autologous Stem cell Transplantation In refractory CD—Low Intensity Therapy Evaluation clinical trial. 
Immune reconstitution will be evaluated using patient-derived blood mononuclear cells at weeks 8 12, 24, 32, and 48 after infusion autologous hematopoietic stem 
cells. Multi-color flow cytometry and optimized multicolor immunofluorescence-like antibody panels will be used to assess the general immune status of the patients, 
as well as the ability to release immune regulatory cytokines at the single-cell level. Mucosal biopsies will be assessed at baseline, weeks 24 and 48. RNA will be 
extracted and will be analyzed on a NanoString FLEX™ gene expression profiling platform, as detailed in the main text. Additional studies could employ a 
multiplexed spatial protein profiling approach based on NanoString digital quantification of tissue proteins to generate a digital replica of the immune topography of 
intestinal biopsies and to gain mechanistic insights into the immune determinants of response after autologous HSCT, with emphasis on the reconstitution of 
plasmacytoid DCs, regulatory T cells, and TCR-Vβ repertoires. Abbreviations: G-CSF, granulocyte colony-stimulating factor; Cy, cyclophosphamide; Flu, fludarabine; 
PBMCs, peripheral blood mononuclear cells; FFPE, formalin-fixed paraffin-embedded; IHC, immunohistochemistry.
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Amplification-Free Gene expression 
Profiling of the Periphery and Tissue
Gene expression profiles reflect the immune milieu and are increas-
ingly being used for immune monitoring purposes and identifying 
predictive biomarkers in patients with cancer. Microarrays have 
traditionally supported the high-throughput analysis of gene and 
miRNA expression, but they are limited by the requirement for 
relatively large quantities of high-quality RNA. Next Generation 
Sequencing (NGS) has become an important discovery tool, and 
the preferred choice for unbiased biomarker discovery of tran-
scriptional signatures associated with disease activity, treatment 
outcomes, and mechanism of action studies of therapeutic agents. 
However, data analysis and interpretation require advanced 
bioinformatics approaches. Quantitative PCR (qPCR) provides 
a more accurate insight into gene expression than microarrays 
and requires lower amounts of RNA. However, the analysis of 
the expression of multiple genes with classical qPCR and digital 
PCR, which can also be used for high-throughput high-precision 
analysis, is more difficult.
NanoString-based molecular “bar coding” enables the high-
throughput analysis of the expression of multiple genes using 
defined panels such as the nCounter™ Human Immunology, 
Human Inflammation, and Human Myeloid Innate Immunity 
Panels. The Human Immunology module could be particularly 
relevant to the post-HSCT immune monitoring of patients with 
CD, given that the ASTIC trial reported treatment-related infec-
tions to be the most frequent serious adverse events during the 
100 days after conditioning and the subsequent follow-up (17). 
The NanoString nCounter™ analysis system detects the expres-
sion of up to 800 genes in a single reaction with high sensitivity 
and linearity across a broad range of expression levels (54). The 
platform utilizes digital detection and direct molecular barcoding 
of individual target molecules using fluorescently labeled capture 
and reporter probes incorporating 35- to 50-base target-specific 
sequences. This technology allows for direct, PCR amplification-
free multiplexed measurements of gene expression from a low 
amount of mRNA (25–300 ng). Different sources of RNA, includ-
ing total RNA, fragmented RNA and formalin-fixed paraffin-
embedded (FFPE)-derived RNA, can be used. This approach is 
suitable for the discovery of gene expression signatures, their 
validation and diagnostic testing in large translational studies.
The Autologous Stem Cell Transplantation 
in Refractory CD—Low intensity Therapy 
evaluation (ASTiClite) TRiAL: An 
Opportunity to investigate immune 
Reconstitution Post Auto-HSCT in CD
Given that reduced intensity mobilization and conditioning regi-
mens are associated with lower morbidity in malignant and AD 
(20, 55–58), the hypothesis that auto-HSCT using a reduced dose 
cyclophosphamide mobilization and low intensity conditioning 
(HSCTlite) will induce regression of ileocolonic ulceration in 
patients with refractory CD compared to standard of care will 
be tested via a soon-to-commence clinical trial (ASTIClite). This 
UK NIHR-funded national multicenter randomized controlled 
clinical trial aims to recruit 99 patients with a 2:1 randomization 
to compare HSCTlite with standard of care. For this, eligible out-
patients with treatment refractory CD will be randomized to auto-
HSCT with cyclophosphamide 1 g/m2 + G-CSF for mobilization 
followed by transplant conditioning with fludarabine 125 mg/m2, 
TABLe 1 | Flow cytometry antibody panels for immune cell reconstitution in CD.
Cell type/subtype Phenotype
CD4+ and CD8+ T cellsa
Naïve CD3+CD4+/−CD8−/+CD45RA+CCR7+
Effector CD3+CD4+/−CD8−/+CD45RA+CCR7−
Central memory CD3+CD4+/−CD8−/+CD45RA−CCR7+
Effector memory CD3+CD4+/−CD8−/+CD45RA−CCR7−
Gut-homing T cells CD3+CD4+/−CD8−/+CD49d+α4integrin+CCR9+
Recent thymic 
emigrants
CD3+CD4+/−CD8−/+CD31+
CD4+ T helper (Th) subsets (option to include CD45RA+/−)a
Th1 CD3+CD4+CD8−CXCR5−CXCR3+
Th2 CD3+CD4+CD8−CXCR5−CCR4+CCR6−
Th9 CD3+CD4+CD8−CXCR5−CCR4−CCR6+
Th17 CD3+CD4+CD8−CXCR5−CCR4+CCR6+CCR10−
Th17.1 CD3+CD4+CD8−CXCR5−CXCR3+CCR6+CCR4
Th22 CD3+CD4+CD8−CXCR5−CCR4+CCR6+CCR10+
Follicular T helper (Tfh) CD3+CD4+CD8−CXCR5+PD-1+ICOS+
Gamma delta T cells CD3+TCRγδ+
CD4+ immunoregulatory T (Treg) cells
CD3+CD4+CD25highCD127lowFoxp3+CCR4+/−CD45RO+/−
Myeloid-derived suppressor cells (MDSCs)—Lineage (Lin) cocktail: 
CD3/CD19/CD20/CD56
Monocytic Lin−HLA-DR−/lowCD11b+CD14+CD15−CD124+
Granulocytic Lin−HLA-DR−/lowCD11b+CD14−CD15+CD124+
Endothelial progenitor Lin−HLA-DR−/lowCD11b+CD124−
Dendritic cells (DCs)—lineage (Lin) cocktail: CD3/CD19/CD20/CD56
Plasmacytoid Lin−CD14−CD123+CD11c−
Conventional Lin−CD14−CD123−CD11c+
innate lymphoid cells (iLCs)—lineage (Lin) cocktail: CD3/CD14/CD19/
CD20
ILC1 Lin−CD127+CD161+CD117−CD294−NKp44−
ILC2 Lin−CD127+CD161+CD294+
ILC3 Lin−CD127+CD161+CD117+CD294−NKp44−
Mast cell progenitors (MCPs)—Lineage (Lin) cocktail: CD3/CD14/CD19/
CD20
Lin−FcεRIα+CD203+CD117+
Natural killer (NK) cell subsets
Cytotoxic CD3−CD56dimCD16+
Cytokine-producing CD3−CD56brightCD16+/−
Monocytes
Classical CD3−CD14highCD16-
Intermediate CD3−CD14highCD16+
Non-classical CD3−CD14+CD16high
B cells/plasmablasts
Naïve CD3−CD19+CD27−IgD+
Switched memory CD3−CD19+CD27+IgD−
Non-switched memory CD3−CD19+CD27+IgD+
Plasmablasts CD3−CD19+CD27highIgD−CD38high
Regulatory B cells CD3−CD19+CD1dhighCD5+CD21+CD24high
T cell responsiveness to stimulation
CD3+CD4+CD8−IL2−/+IL4−/+IL17−/+TNFα−/+IL10−/+IFNγ−/+
CD3+CD4−CD8+IL2−/+IL4−/+IL17−/+TNFα−/+IL10−/+IFNγ−/+
aCD4 differentiation and helper subsets can be gated upon after Foxp3+CD25hiCD127low 
Treg cells have been excluded from the CD4+ T cell parent population.
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cyclophosphamide 120  mg/kg, and rabbit anti-thymocyte 
globulin 7.5  mg/kg (total doses) versus standard of care and 
followed for 48 weeks. The reduced doses of cyclophosphamide 
in the mobilization and conditioning regimens are based on the 
concerns raised following the single case of TRM in the original 
ASTIC trial, which may have been related to cumulative toxicity 
from higher mobilization dose of cyclophosphamide (4  g/m2) 
followed by the transplant conditioning (21, 22). It is hoped that 
this measure will improve overall safety and reduce the likelihood 
of neutropenic sepsis during the mobilization phase, which may 
be performed as an outpatient procedure.
The standard care group will be able to receive any licensed 
biologic, immunosuppressive or nutritional therapy for CD at 
the discretion of the treating physician. Pre-specified interim 
analyses will be undertaken to confirm that the mobilization 
regimen is effective for stem cell harvest with no negative impact 
on disease activity. Colonoscopy and MRI at week 24 will assess 
the requirement for re-initiation of maintenance of anti-TNF 
therapy in those with evidence of disease activity post auto-
HSCT. Immunological profiling of blood and mucosa before and 
after HSCTlite will identify its mechanism of action. It is expected 
that HSCTlite will have an acceptable side-effect profile.
Additional secondary clinical endpoints will be the impact of 
HSCTlite on clinical disease activity, steroid requirements, qual-
ity of life, and the presence of adverse/serious adverse events, as 
compared to standard of care [and historical HSCT, as observed 
in ASTIC (16, 17)]. Exploratory endpoints will be the safety and 
efficacy of maintenance anti-TNF therapy in those patients with 
the recurrence of endoscopic disease after HSCTlite.
At the core of this study is comprehensive and informative 
immunological profiling of the periphery and mucosa before and 
after treatment (Figure 2). Profiling will be focused on generating 
insight into the pathogenesis of CD, the responsiveness, and res-
toration of responsiveness to anti-TNF therapy in patients with 
endoscopic disease recurrence and the immunological events 
that precede recurrence of disease and occurrence of resistance 
to anti-TNF therapy in patients that relapse after auto-HSCT.
Reconstitution of immune potential is being monitored by 
determining the re-appearance of monocyte subsets, T  cell 
subsets (“helper,” “cytotoxic,” naïve, central memory, effector 
memory, regulatory, RTEs), B cell subsets, and NK cell subsets 
(cytokine-secreting CD3−CD56brightCD16+/− and cytotoxic; 
CD3−CD56dimCD16+) using multi-parameter flow cytometry. 
Representative panels that can be used for the monitoring of 
immune reconstitution in patients with CD following auto-HSCT 
are summarized in Table 1, the ability to deliver which will be 
dependent on the instrumentation available in the analytical 
laboratory. Comprehensive protocols relating to flow cytometric 
analysis have been published previously (48, 49).
Combined with post-transplant vaccination, the immune recon-
stitution of “ASTIClite” will therefore aim to establish whether the 
effect of AHSCT is merely temporary downregulation of immunity 
or whether there is a significant component of immune reset.
CONCLUSiON
Based on clinical trials and EBMT registry data, auto-HSCT 
represents a promising therapy for patients with severe resistant 
CD. Prolonged responses have been achieved in some patients 
that have otherwise been resistant to conventional treatments 
and biological therapies. In the patients who relapse, there 
appears to be a re-sensitization to previous agents, consistent 
with a “setting back of the immunological clock.” Previous 
clinical trials and case series report a relatively high relapse 
rate and high frequency of serious adverse events. Future trials 
will assess the efficacy and safety of lower intensity mobiliza-
tion and conditioning regimens and the benefit of protocoled 
introduction of maintenance therapy in patients who relapse 
after auto-HSCT.
In addition, clinical trials of auto-HSCT provide a unique 
opportunity to characterize the nature of immune reconstitution 
as well as the interaction between the peripheral and mucosal 
immune system in CD. This will allow deep interrogation and 
characterization of the localized mucosal immune environment 
in patients with disease before and after auto-HSCT during 
ASTIClite, as well as the immunome of the periphery (by profil-
ing peripheral blood mononuclear cells, PBMCs) before and 
after auto-HSCT and during the progression toward disease 
relapse.
Recently, the EBMT and European Crohn’s and Colitis 
Organi sation have published a review to encourage and guide 
inter-specialty collaboration in both clinical and scientific 
development of this auto-HSCT in CD (59). Thus, in addition to 
therapeutic benefits, destroying and re-building the dysfunctional 
immune system and mucosal environment, a program of modern 
scientific investigation carefully scheduled around auto-HSCT 
may yield valuable insights into the etiology, pathogenesis, and 
mechanisms of treatment resistance in CD.
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